fenofibrate / Generic mfg. - LARVOL DELTA

STaRT: Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia (clinicaltrials.gov) - P=N/A | N=2382 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Atherosclerosis • Cardiovascular

The mechanism of PPARα-mediated cholesterol metabolism in regulating paclitaxel resistance in ovarian cancer cells (EACR 2025) - "PPARα expression was modulated through knockdown, overexpression, and treatment with the pharmacological inhibitor GW6471 or agonist fenofibrate.Result and Resistant cells exhibited fewer but larger lipid droplets (P9)...Simvastatin treatment reduced resistance (P<0.01), linking Chol metabolism to chemoresistance... PPARα regulates PTX resistance in ovarian cancer by modulating Chol metabolism. Targeting PPARα and its downstream pathways may offer novel therapeutic strategies to overcome chemoresistance."

Dyslipidemia • Gynecologic Cancers • Metabolic Disorders • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • ABCC1 • ACAT1 • PPARA

Development of Fenofibrate Solid Dispersion via Hot Melt Extrusion and 3D Printing Technologies. (PubMed, Pharm Dev Technol) - "The in- vitro drug release for the 3D printed tablets and capsules was increased 2-fold as compared to pure fenofibrate. Statistical comparisons further supported these findings, highlighting infill density as a tunable parameter for modulating release kinetics."

Journal

Application of Solvent Evaporation to Generate Supersaturated Lipid-Based Formulations: Investigation of Drug Load and Formulation Quality. (PubMed, Pharmaceutics) - "Both approaches were compared in this work investigating two different LBFs loaded with the BCS-class II drugs celecoxib and fenofibrate. This analysis revealed that the DCM content exceeded regulatory requirements, with up to 21,883 ppm DCM in the formulations. Overall, the relatively high residual DCM concentration and the suboptimal physical stability do not make the approach easily usable for generating supersaturated lipid-based formulations."

Journal

Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases. (PubMed, Neurooncol Adv) - "Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed."

Journal • Brain Cancer • Embryonal Tumor • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Medulloblastoma • Neutropenia • Oncology • Pineoblastoma • Solid Tumor

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: Lindsay Ferguson, MD | Recruiting ➔ Suspended

Trial suspension • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Drug Solubility in Human Colonic Fluids and Comparison to Small Intestinal and Simulated Fluids. (PubMed, Mol Pharm) - "Therefore, this study aimed to measure and compare the apparent solubility of eight drugs with varying physicochemical properties (apixaban, danoprevir, dexloxiglumide, febuxostat, fenofibrate, rofleponide, ticagrelor and tofacitinib) in pooled aspirates from the proximal human colon and small intestine, along with simulated media and buffers commonly used in solubility assessment. Solubilities of all other drugs were predicted reasonably well in blank buffers and simulated media. The results generated in this study may serve as reference data for the validation of improved in vitro and in silico tools for colonic drug solubility prediction."

Journal • Gastrointestinal Disorder

Severe Hypertriglyceridemia Secondary to Long-Acting Asparaginase in Pediatric Patients With Acute Lymphoblastic Leukemia. (PubMed, J Pediatr Hematol Oncol) - "Management included hydration, a low-fat diet, omega-3 supplements, fenofibrates, statins, and levocarnitine...In conclusion, severe hypertriglyceridemia can occur after long-acting asparaginase and is typically asymptomatic and transient, not requiring a pause or modification in treatment. We recommend monitoring for hypertriglyceridemia closely in patients with risk factors who are resuming long-acting asparaginase therapy after triglyceride levels fall <1000 mg/dL."

Journal • Acute Lymphocytic Leukemia • Cardiovascular • Critical care • Dyslipidemia • Heart Failure • Hematological Malignancies • Hypertriglyceridemia • Hypoglycemia • Leukemia • Oncology • Pediatrics • Severe Hypertriglyceridemia

Genetically Determined PPARA Expression Modulates Fenofibrate Response on Lipid Profile—A Pharmacogenetic Trial (ADA 2025) - "These precision medicine finding supports the concept that genetically determined PPARA expression affects fenofibrate response. Nonetheless the observed differences are unlikely to fully explain the large CVD and DR effect seen in previous studies. Further research is needed to dissect additional mechanisms and tissue-specific eQtGS effects."

Biomarker • Late-breaking abstract • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • APOA2 • APOB • PPARA

Refining Socioeconomic Analysis for Cardiovascular Disease in Type 2 Diabetes—Why Postcodes/Zip Codes Are Too Large for Meaningful Insights (ADA 2025) - "The conventional approach, relying on SES indices for large geographical units (e.g., postcodes), may overlook SES effects detectable at smaller scales. We analyzed Australian participants from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study... Assessing SES at smaller geographical scales offers a more nuanced understanding of socio-economic disparities and their health impacts. Our approach highlights the need for greater granularity in SES analysis to reveal trends in health outcomes."

HEOR • Late-breaking abstract • Omic analysis • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Protein and mRNA Comparison in Complications of Type 2 Diabetes—Integrating Proteomics with Transcriptomics (ADA 2025) - "We now measured their mRNA expression in T2D patients with and without CX. RNA was extracted from citrate plasma samples of 542 people with T2D from the Fenofibrate Intervention and Event Lowering in Diabetes trial (Age: 62±7 yrs; T2D duration: 6±6 yrs; HbA1c: 6.8±1.3%)... These findings underscore the importance of integrating transcriptomic and proteomic analyses to better understand the molecular mechanisms driving vascular complications in T2D and to identify potential therapeutic targets."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CLU • FERMT3 • TLN1

The Relationship of Mitochondrial DNA Copy Number with Cardiovascular and Microvascular Complications in Patients with Type 2 Diabetes—A Field Substudy (ADA 2025) - "This study investigates whether mitochondrial DNA copy number (mtDNA-CN) in whole blood can serve as a biomarker for these complications. mtDNA-CN was measured in the DNA extracted from whole blood samples of 497 T2D adults from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial... Mitochondrial DNA copy number could serve as a biomarker for assessing microvascular disease risk in T2D patients."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Immune regulation of TLR4/MYD88/ NF-κB/AP1/IL-6 pathway and modulation of aldosterone/PPARα receptors by eplerenone and fenofibrate in ovarian ischemia reperfusion induced injury. (PubMed, Int Immunopharmacol) - "EPL and/or FEN had ameliorative properties against OIR induced harmful effects."

Journal • Cardiovascular • Gynecology • Reperfusion Injury • Women's Health • CASP3 • IL6 • MYD88 • PPARA • TLR4

Association of Haptoglobin Levels and Phenotype with Cardiovascular Disease in Adults with Type 2 Diabetes—A FIELD Trial Substudy (ADA 2025) - "HP levels and phenotype help to identify T2D patients at high CVD risk for treatment, especially those with HP 1-1 phenotype."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • HP

PPARα activation attenuated heat-induced myocardial injury in mice. (PubMed, Ecotoxicol Environ Saf) - "Then, pre-treatment with PPARα agonist fenofibrate significantly mitigated myocardial injury, accompanied with improved mitochondrial function in the myocardial tissues. In addition, PPARα activation may restore the mitochondrial homeostasis through enhancement of both antioxidation and mitophagy. These findings will highlight the pivotal role of PPARα in alleviating heat-induced myocardial injury and cardiovascular incidence, providing valuable target for drug development to prevent/treat heat stress-related diseases."

Journal • Preclinical • Cardiovascular • PPARA

Online tool for cross-sectional and longitudinal comparison of socio-economic status indices based on postcodes in Australia. (PubMed, Intern Med J) - "Our SES assessment tool provides a more nuanced understanding of SES disparities and their implications for health and well-being."

Journal • Diabetes • Metabolic Disorders

Impaired ketogenesis ties metabolism to intestinal stem cell dysfunction in Ulcerative Colitis (BSG 2025) - "In UC organoids, fenofibrate (PPARα agonist), induced HMGCS2 expression (p<0.001) and βHB production (p<0.05)... We provide the first combined evidence of mitochondrial dysfunction and ketogenesis failure ('primary' and 'backup' energy failure) in UC. Crucially, restoring ketogenesis reverses the ISC pathogenic defect thus, opening a new 'immuno-metabolic' therapeutic approach in UC. * Single Cell Energetic Metabolism by Profiling Translation Inhibition Figure 1."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Ulcerative Colitis • HMGCS2 • HSPD1 • PPARA • VDAC3

Fenofibrate Exerts Protective Effects in Diabetic Retinopathy. (PubMed, Curr Eye Res) - "These effects contributed to the stabilization of cellular homeostasis, potentially slowing disease progression. Fenofibrate offers significant protective effects in diabetic retinopathy by reducing inflammation and oxidative stress, promoting autophagy, and inhibiting ferroptosis, making it a promising therapeutic option for managing the disease."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Retinal Disorders

VRd MM Fibrate: Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) (clinicaltrials.gov) - P4 | N=44 | Not yet recruiting | Sponsor: Tanta University

New P4 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Pain

Comprehensive identification of crucial biomarkers and therapeutic targets in cholestasis via integrated single-cell RNA and transcriptome sequencing analysis. (PubMed, Mamm Genome) - "Drug repurposing analysis identified dexamethasone, fenofibrate, promazine, and SB-590,885 as potential therapies. This study identifies IL32, CRIP2, ANXA2, and VWF as pivotal biomarkers and therapeutic targets for cholestasis, offering new avenues for targeted interventions."

Biomarker • Journal • Cholestasis • Hepatology • Liver Failure • ANXA2 • IL32

INTEGRATING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR A AND CIRCADIAN RHYTHM INSIGHTS AS NOVEL UNDERLYING MECHANISMS OF OSTEOARTHRITIS (EULAR 2025) - "Recent findings from our group pointed towards Peroxisome Proliferator-Activated Receptor α (PPARα) as a potential DMOAD target mechanism for knee OA, through its activation with Fenofibrate (FN), a PPARα agonist commonly used for dyslipidemias treatment in humans... Knockdown of PPARα was efficient up to 96h post synchronization with Dexamethasone... These findings provide a novel approach to study molecular function of PPARα in the context of CR, which are intended to 1) explain the implication of PPARα on the disease, and 2) understand the molecular basis of the beneficial effect of PPARα activation."

Dyslipidemia • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • ARNTL • BMAL1 • CDKN1A • IL1B • PPARA

Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies (EULAR 2025) - "Drugs examined less than 5 times, including spironolactone, doxycycline, liraglutide, thiazolidinediones, anti-histamines, ticagrelor, β-blockers, coumarins, anti-IL1, anti-IL6, sodium bicarbonate and calcium gluconate, fenofibrate, somatropin, pentosan polysulfate, insulin, N-acetylcysteine, naltrexone, bromelain, fish oil, L-carnitine, folate, vitamin C, and vitamin K showed similar results (data not shown). Many authorised drugs have already been investigated to be repurposed for the treatment of OA, of which the most extensively investigated mainly targeted the inflammatory and bone endotype. Short-term studies investigated almost exclusively symptom-modifying effects, whereas most long-term studies investigated structure-modifying effects as well. However, long-term studies investigating structural-modifying effects of colchicine, methotrexate, and hydroxychloroquine are lacking."

Clinical • Review • Immunology • Oncology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet-induced steatotic liver disease. (PubMed, Mol Pharmacol) - "SIGNIFICANCE STATEMENT: We found that long-chain fatty acid overload was a characteristic of high-fat diet-induced fatty liver, and fenofibrate ameliorated high-fat diet-induced fatty liver by upregulating enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase to promote the oxidation of long-chain fatty acids, especially erucic acid. This study may contribute to the use of fenofibrate in the treatment of fatty liver disease."

Journal • Acute Myelogenous Leukemia • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • EHHADH

Modulation of interleukins 38 and 1 Beta gene expression by N-(4-benzoylphenyl)-5-nitrofuran-2-carboxamide in Triton WR-1339 induced hyperlipidemic rats. (PubMed, Lipids Health Dis) - "In conclusion, all novel compounds and fenofibrate demonstrated significant antihyperlipidemic properties. Among the three compounds, NF4BP showed the highest elevation in the expression levels of anti-inflammatory marker IL-38 accompanied by down regulation of proinflammatory markers. Understanding the impact of these compounds on inflammatory markers' expression is critical for developing effective therapeutic strategies for managing hyperlipidemia-associated complications. Hence, targeting these inflammatory pathways by these compounds may offer new avenues for the prevention of dyslipidemia complications."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Oncology • CRP • ICAM1 • IL1B • IL1F10 • IL6 • TNFA • VCAM1

Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial. (PubMed, BMC Pharmacol Toxicol) - P4 | "Both fenofibrate and curcumin are effective at decreasing lipid profiles and improving inflammatory markers in patients with type 2 diabetes. Fenofibrate might have a superior effect in reducing waist circumference, decreasing fetuin-A, and increasing sirtuin 1."

Clinical • Journal • Cardiovascular • Diabetes • Dyslipidemia • Gestational Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • SIRT1